

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: March 27, 2019</p>	
<p>Re.: USFDA Inspection completed at Alidac Pharmaceuticals</p>	

Dear Sir / Madam,

We wish to inform that the USFDA conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals Ltd., the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from 18th to 26th March, 2019. The inspection concluded with one observation. Alidac is a 100% subsidiary of Cadila Healthcare Ltd. There was also a separate in-vitro BE inspection conducted by the Office of Study Integrity and Surveillance branch of US FDA for the same product which concluded with one observation.

The Company is addressing these observations and is confident of getting the product approval at the earliest.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,
Yours faithfully,

For, **Cadila Healthcare Limited**
Dhaval Soni
Company Secretary